HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that significant state Medicaid reform efforts in Louisiana and Rhode Island will likely face challenges in light of the nation's economic downturn, particularly as Medicaid populations grow.

According to the recent Georgia, Alabama & Louisiana Health Plan Analysis, state officials believe that a re-structured Medicaid program, giving beneficiaries a choice of plans, will provide residents better health outcomes for less money than the present fee-for-service, one-size-fits-all program. Louisiana would contract with at-risk managed care plans and primary care networks. The plan is currently under review by the Centers for Medicare & Medicaid Services (CMS) and includes pilot programs in four regions with an expanded experiment in the state's Lake Charles region. Reform is much needed in the state as it currently ranks last or nearly last in national health rankings.

"With dismal health outcomes and rising Medicaid costs, managed Medicaid is past due in Louisiana, though plans will likely face hurdles in the coming year because of the economic climate and growing demand," said Jan Shuxteau, analyst with HealthLeaders-InterStudy. "However, once approved, the prospect of hundreds of thousands of covered lives will attract significant interest from managed care organizations, particularly those that already have experience in the state-sponsored insurance sector."

According to the Winter 2009 New England Health Plan Analysis, Rhode Island has received CMS approval to operate its Medicaid program under what is known as a "global cap." Under this five-year deal, the state receives a set amount of funding from the federal government, but is responsible for costs that go over that amount. In return, Rhode Island Medicaid would have flexibility to design benefits and manage the Medicaid program outside the usual rules.

"Gov. Carcieri is driving Rhode Island's Medicaid reform efforts, but there are many who feel the cap approach carries too much risk for the state, especially with the state's high unemployment rate," said Ric Gross, analyst with HealthLeaders-InterStudy. "However, the governor contends the expansion of at-home and community-based services for the elderly enabled under the plan's flexibility will help them avoid more costly, longer term costs, such as nursing home care."

Why Pharmaceutical Companies Need Health Plan Analysis

Health Plan Analysis identifies key health plan trends, allowing pharmaceutical companies to create comprehensive strategic plans and sales strategies at state and local levels. Updated quarterly, Health Plan Analysis provides a detailed look at plan design and financials, as well as information about mergers, legislation and other influencers driving healthcare in a particular region.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Lisa Osgood                               Elizabeth Marshall   HealthLeaders-InterStudy                  Decision Resources, Inc.   781-296-2606                              781-296-2563   losgood@hl-isy.com                        emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: HealthLeaders-InterStudy

CONTACT: Lisa Osgood of HealthLeaders-InterStudy, +1-781-296-2606,
losgood@hl-isy.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe

View Now